Search / Trial NCT00000872

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Virus Replication Hiv 1 Drug Therapy, Combination Zidovudine Nevirapine Stavudine Hiv Protease Inhibitors Cd4 Lymphocyte Count Lamivudine Rna, Viral Reverse Transcriptase Inhibitors Anti Hiv Agents Viral Load Nelfinavir

ClinConnect Summary

This study examines the antiretroviral activity of ZDV/3TC/NVP in vertically-infected infants and children aged 15 days up to 2 years, and ZDV/3TC/NVP/ABC in vertically-infected infants and children aged 30 days up to 2 years. This study will assess HIV-1 and CD4/CD8 T-cell kinetics, activation, and maturation. It will also test the concept that early (younger than 3 months of age) use of potent, combination antiretroviral therapy will allow the long-term control of viral replication with preservation of normal immune function. \[AS PER AMENDMENT 3/11/98: This study will also examine the an...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Children may be eligible for this study if they:
  • Are 15 days to 2 years old.
  • Have consent of parent or legal guardian.
  • Are HIV-positive.
  • Exclusion Criteria
  • Children will not be eligible for this study if they:
  • Have certain infections which require treatment during the study.
  • Have received certain medications.

Trial Officials

Katherine Luzuriaga

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

New Orleans, Louisiana, United States

Baltimore, Maryland, United States

Baltimore, Maryland, United States

Boston, Massachusetts, United States

Springfield, Massachusetts, United States

Worcester, Massachusetts, United States

Houston, Texas, United States

Philadelphia, Pennsylvania, United States

New York, New York, United States

Gainesville, Florida, United States

Detroit, Michigan, United States

Norfolk, Virginia, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials